Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vytrus BiotechXMAD:VYT +4.00%66 Altman Z-Score is 18.01 as of Aug. 24, 2026, which is 306% above its 10-year median of 4.44. GuruFocus rates XMAD:VYT with a GF Score™ of 66/100 and a GF Value™ of €5.67 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 929 Biotechnology companies, Vytrus Biotech ranks better than 86.54% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 18.01 is strong.
Vytrus Biotech has a Altman Z-Score of 18.01, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Vytrus Biotech's Altman Z-Score or its related term are showing as below:
XMAD:VYT'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.7 Med: 4.44 Max: 18.01
Current: 18.01
During the past 8 years, Vytrus Biotech's highest Altman Z-Score was 18.01. The lowest was 2.70. And the median was 4.44.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Vytrus Biotech Altman Z-Score Related Terms
Vytrus Biotech Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, RVMD: Altman Z-Score Comparison
For the Biotechnology subindustry, Vytrus Biotech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Vytrus Biotech's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.2463
+
1.4
*
0.1976
+
3.3
*
0.2167
+
0.6
*
26.9247
+
1.0
*
0.571
=
18.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Vytrus Biotech (XMAD:VYT) has a Altman Z-Score of 18.01 as of Aug. 24, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Vytrus Biotech and its competitors. This is 306% above median its historical median of 4.44. Over the past decade, Vytrus Biotech's Altman Z-Score has ranged from 2.70 to 18.01. According to the industry distribution chart, Vytrus Biotech ranks #125 out of 929 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Vytrus Biotech's Altman Z-Score too high?
Vytrus Biotech's current Altman Z-Score of 18.01 is 306% above median its 10-year median of 4.44. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 18.01. The Biotechnology industry median Altman Z-Score is 2.74. Vytrus Biotech's value of 18.01 is 557.3% above this industry median. Based on the distribution chart, Vytrus Biotech ranks #125 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #125 out of 929 companies for Altman Z-Score. This places Vytrus Biotech in the top 14% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.74. Vytrus Biotech's value of 18.01 is 557.3% above this benchmark. Historically, Vytrus Biotech's own Altman Z-Score has ranged from 2.70 to 18.01 over the past decade. While the company's 10-year median is 4.44 vs. the industry median of 2.74, Vytrus Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.74, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current Altman Z-Score of 18.01 is 557.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current Altman Z-Score is 18.01, which is 306% above median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.67, compared to a current price of €15.60 — trading 175.1% above its estimated fair value. The current Altman Z-Score is 18.01, which is 306% above median its 10-year median of 4.44 and 557.3% above the Biotechnology industry median of 2.74. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Altman Z-Score is 18.01 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €15.60 is trading 175.1% above its estimated GF Value™ of €5.67.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Altman Z-Score: 18.01 (306% above median its 10-year median of 4.44)
GF Value™: €5.67 vs. price of €15.60 (175.1% above fair value)
Industry Position: 557.3% above the Biotechnology median (#125 of 929)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score
Get the complete analysis for XMAD:VYT
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
